Category: Uncategorized

A technology innovation company, Renalyx is inventing inclusive solutions to confer comprehensive renal care. Established in 2012, the company’s end in view is to curate top-notch programs to reach, care and treat patients suffering from diabetes, chronic kidney diseases, and hypertension. Considering the cost and perplexities in the medical process of dialysis, Dr. Shyam Vasudeva Rao and a team of professionals took the initiative of building an economical and get-at-able renal solution that can ensure better treatment and quality of life. These made-in-India machines are particularly fashioned to conduct early detection of CKD with a point of care solution.

Since diabetes is one of the underlying factors causing deaths in COVID 19 patients. Timely diagnosis, management, and treatment of the disease can save millions of lives. The team of Renalyxis leveraging technology to bridge the gap between patients.

The three neoteric products composed by Renalyx are:

• Point of Care: Renalyx has specially designed a program to clip the screening of diabetic and hypertensive in patients. These strip-based urine tests that are used to detect chronic kidney disease (CKD) problems at an early stage are calorimetrically analyzed by an App running on an Android mobile phone.
• Renal Information Management System: Renalyx-Care uses a cloud-based Nephrology Information System to maintain patient records. It educates and advises the patients about treating chronic kidney disease (CKD), helping them to put a pause on its progression from Stage-1 to Stage-4. It helps the patients pick out the right diet, medicines, and counseling.
• Dialysis Machine: The device is created to remotely monitor the vital statistics during the dialysis process as entailed by qualified nephrologists. This program has proven to be beneficial in treating CKD stage-5 (ESRD) patients by a connected dialysis machine.

The cloud-based feature of these solutions allows it to be connected with the mobile app, helping the doctors to have access to the patients’ health records and monitor them from any place and anytime.

This Bangalore-based firm has partnered with some of the leading organizations like IIT KHARAGPUR, PESIT, EHEALTH ENABLERS, Vinyas Innovative Technologies Pvt. Ltd., and BMSIT, SWASTHYA MED – C. In its incredible nine years of existence, Renalyx has won many accolades and significant media attention. It secured second place for Innovation by Indian Innovation Growth Program for the Year 2015 which was jointly conducted by the Department of Science & Technology, Government of India, and Lockheed Martin Corporation. It also won an award for Technology Innovation (2015-2016) by the Government of India, Ministry of Chemicals and Fertilizers for the Dialyser development project along with I.I.T. Kharagpur. The company has successfully attained ISO 13485 & CE Certification.

Renalyx has recently inked a Techno commercial agreement to exclusively manufacture and market the Hemodialysis machine with Bharat Electronics Bangalore a Govt. of India enterprise in early 2021.

“Our mission and vision are lucid. We aim to help people lead a quality life by enabling trouble-free and affordable dialysis treatment through our nonpareil renal care solutions and measures. We aim to expand and build a passionate team that nurtures professionalism, skills, and ethical standards,” states Dr. Shyam Vasudeva Rao, Founder & Director, Renalyx.

The future Renalyx envisioned, is inclined towards creating innovative and inclusive solutions that are cost-efficient and delivers comprehensive renal care. The team has set its sight on constantly enhancing the potentiality of the solutions and innovate devices to meet the evolving requirements and expectations of the customers.

“Our experience with NASSCOM CoE has been an interactive and interesting one,” says Dr. Shyam Vasudeva Rao, Founder & Director, Renalyx.

For any further information\query you can write to us at Co-innovate@nasscom.in.

COVID-19 pandemic brought to fore the long-standing gaps in the Indian healthcare industry.  The country endured a tough time in meeting the challenges caused by the critical shortage of ventilators particularly during the second wave, one of the main causes that spiked the mortality rates. In such an uncertain environment, the nation witnessed a promising collaboration between industry giants, innovative startups and the government to fill in the gaps prevailing in the healthcare industry. Medical innovation on the other hand has been extensively promoted to beget effective solutions which can support hospitals and healthcare providers in the battle against COVID-19.

Biodesign Innovation Labs, a startup associated with Center of Excellence – IoT& AI, which is a joint initiative of MeitY and NASSCOM, came up with a frugal yet potent innovation called RespirAID- a smart life-sustaining automated respiratory assist device. It is a reliable, affordable, adaptable device that can be used in emergency care, transport ventilation, ambulances, post-operative care, and intraoperative care. It played a vital role in supporting ICUs during the shortage of sophisticated ventilators. It proved of great help during the second COVID wave in India as it helped many hospitals manage patients by maintaining the vitals with high FI02 and PEEP requirements, saving the lives of patients.

How does it help!

• RespirAID aids the primary function of ARDS patient management.
• Its UPS enables trouble-free mobility of the patient within the hospital as well as during examinations & surgeries.
• The safety alarm system draws the attention of the caretakers during an emergency
• The device displays real-time breath rates, tidal volume, inspiratory/expiratory ratio, peak inspiratory pressure that empowers operators to make quick decisions and PEEP.

An automated-portable breathing support system, RespirAID employs a ventilation strategy known as positive pressure mechanical ventilation andto monitor the crucial respiratory parameters. Patients with a higher risk of lung collapse can find solace in RespirAID. It will potentially save thousands of lives.

The passion to leverage technology to root out the loopholes in the healthcare system inspired tech-savvy siblings Adithya Pasupuleti and Gautham Pasupuleti establish Biodesign Innovation Labs- a medical device and healthcare technology company focused on developing innovative yet affordable medical tech solutions that can save lives and improve the quality of life for all.

“With our products RespirAID, ResPAP and other life-giving solutions we intend to save millions of lives around the world. We have one goal and that is to diligently work towards building an ecosystem where patient care is cost-effective, within reach, and downright,” says GauthamPasupuleti, CEO & MD, Biodesign Innovation Labs.

The unique characteristics of this tech-driven medical device have stirred a buzz in the hospital industry. RespirAID’s efficacy of bringing about an equilibrium in the medical sector has bagged Biodesign Innovation Labs humongous appreciations and honours. Both public and private hospitals across the country have deployed their products on a pilot as well as a commercial basis. It owns a solid customer base consisting of enterprises from the private sector, government, NGOs, CSRs and channel partners. Remidio is one of the partner companies of Biodesign Innovation Labs, collaborating for the mass manufacturing of ventilators.

Biodesign Innovation Labs has accomplished several milestones since its inception in 2017. It made it to the top 10 of the shortlisted startups in the Qualcomm Design in India Challenge 2019 cohort, bagged the BIRAC BIG Grant & Nidhi Prayas Grant, declared a finalist in challenges like Ayushman Bharat PM Jay & Tata Social Enterprise Challenge and won the CAMTech Awards. It has recently won the Cisco Global Problem Solver Challenge 2021- Pandemic Response Prize of USD 50,000.

“We are fortunate to get the opportunity to work and evolve under the mentorship of industry leaders who share the same objective of making healthcare accessible and affordable and develop lifesaving innovations and technology,” he adds.

Biodesign Innovation Labs envisions a strategic innovation roadmap where it aims to persistently invent lifesaving solutions to shape the future of the healthcare ecosystem. Using innovative measures the company anticipates revamping respiratory care, critical care, and emergency care and axe out the pitfalls of the healthcare industry, in India and abroad. In a word, the team is marching towards its goal of building value for its customers and aggrandize the quality of care, making healthcare accessible & affordable.

“NASSCOM CoE has provided us great support with connections to industry members such as AstraZeneca (Bangalore). We developed several other connections which were important for us in terms of collaboration and for our business. We are very grateful for their facilitation support and mentorship,”

For any further information\query you can write to us at Co-innovate@nasscom.in.

John Hagel, a well-known management consultant and author has rightly said that if we use the robotics technology correctly we might not only be able to evolve a form of work that taps into our uniquely human capabilities but restore our humanity as well. As we mull over this catchphrase, we realize that the inception of robotic solutions has made industrial operations a lot more comprehensive and accessible than before. Industry experts are making every effort to bring about a correlative understanding between robots and humans to strengthen the precisions, workability, durability, and versatility. These modern requirements and innovations have equipped worker’s safety and boosted industry endeavours to a great extent.

Tanuj Jhunjhunwala and Vineet Upadhyay are two hard-core marine robotics enthusiasts who took a keen interest in leveraging robotics technology to create a paradigm shift in underwater inspections. They have conceptualized the idea of using indigenously manufactured and remotely operated vehicles (ROVs) to support the underwater robotic inspection and survey solutions for industrial sectors in India. Their passion for technology and innovation incited them to establish Planys Technologies-an IIT Madras incubated company that provides submersible robotic inspection and survey solutions.

The duo along with a powerful and adroit team have framed disruptive, perceptive, and cost-effective marine robotics by amalgamating the unique underwater Non-destructive testing (NDT) methods and AI-enabled post-inspection analytical digital reporting dashboard. The company’s unmanned inspection solution supports HD marine videography, murky water inspection,Environmental Monitoring, Archaeological Survey, robotic cleaning and others. Through Non-Destructive Testing (NDT), Ultrasonic, Magnetic, and SONAR sensors the company offers its clients unique insights into the definitive health of underwater structures.

Planys Technologies emerged as the first runners up in the Qualcomm Design in India Challenge 2020- an initiative by Qualcomm that encourages design houses and product companies to invent useful and innovative hardware product designs incorporating Qualcomm SoCs pl and technologies.

“It was an honour to be selected and work with a tech giant like Qualcomm. The cohort had several innovative startups from different sectors. We worked with Qualcomm’s technical team to develop the IOUT solution. The program was meticulously organised despite COVID challenges. They also organised some highly informative workshop sessions by professionals. Overall a great platform boosting the Make-In-India initiative,” states Tanuj Jhunjhunwala, Co-Founder, Planys Technologies.

For the time to come, Planys Technologies is laying the groundwork for its future endeavours. The team is thought showering ideas to formulate revolutionary NDT techniques and products that have the power to further change the status quo of underwater inspection. They aim to further strengthen their presence overseas and explore international opportunities. The company is all geared up to set-up offices in different regions of India and abroad and widens its footprints across the global market. The company has extended its services to Ports/terminals, Oil & Gas, Process Industries (desalination, power, and chemical plants), Desalination/ Power, and Dam & Bridges – India’s critical infrastructure.

Planys Technologies has grown progressively, acquiring more than 75 customers across India, Europe & the Middle East. Based in Chennai, the startup has launched its operation in Saudi Arabia and Netherlands. Its customer base consists of the state governments and leading big guns of the industry including L&T Shipbuilding, Indian Oil, TATA Steel, HPCL, PSA Singapore, Chennai Port Trust, and several others.

It has raised two rounds of investment, Seed round of INR 1.75 Crores in Jan. 2016 from Keiretsu Forum (Singapore and Chennai) and a Pre-Series A of INR 14 Crores in Jan. 2018 from ONGC, Ranjan Pai, and Kris Gopalakrishnan. Along with financial gains, Planys’ pioneering initiative has secured it several national & international awards & accolades such as ‘Young Entrepreneurship Award 2016’ by Takeda Foundation Japan, ‘Aegis Graham Bell Jury Choice Award 2020’, ‘National Startup Award 2020’, ‘National Entrepreneurship Award 2019; and many more. In five years, the company has delivered 160+ assets,developed six products, filed 20+ patents, and inspected 40+ bridges for a state highways department, few crucial railways bridges across different zones, and few crucial dams in Rajasthan and Gujarat.

“Our one-of-a-kind AI enabled digital reporting has been lauded by several key stakeholders and steadily it is bringing about a shift in the inspection arena to digitalise inspections! This innovative solution by Planys helps asset owners in increasing efficiency and forecast maintenance measures,” Vineet Upadhyay, Co-Founder, Planys Technologies.

The prime movers of Planys Technologies are working towards disrupting the global underwater inspection arena by inventing ground-breaking solutions

“It has been amazing to be a part of the NASSCOM CoE community, we have leveraged the wonderful ecosystem of innovation that they have created.Through their support, we have discovered and strengthened several of our domain capabilities. I believe it is an exemplary phenomenon of the ‘Digital India’ initiative and every budding startup should join hands with them to achieve greater heights,”states Tanuj Jhunjhunwala, Co-Founder, Planys Technologies.

For any further information\query you can write to us at Co-innovate@nasscom.in.

It is an undeniable fact that the COVID situation has pushed technology and innovation over the edge and has set off a disruption that humans have not seen in decades. This era has witnessed the maximum technology utilization and its wide-scale adoption. The disruption caused was indeed a wake-up call for the healthcare ecosystem to expedite digital transformation.

Since tests have surfaced to be the first and foremost step to control the spread of COVID 19, developing rapid and reliable testing tools has become extremely necessary. We have seen the healthcare industry, innovators, technology leaders, and the global community banding together to pioneer technological applications and initiatives to hasten diagnosis and treatment.

A month ago, the DRDO center for Artificial Intelligence and Robotics (CAIR) announced the launch of “ATMAN AI”-an Artificial Intelligence algorithm that is capable of detecting the presence of COVID-19 disease in Chest X Rays. DRDO developed this AI-based diagnostic tool with the support of the Bangalore-based startup 5C Network & HCG Academics. 5C Network has successfully deployed ATMAN AI at zero cost across its entire client base of 1000+ hospitals and diagnostic centres in 27 states in India. This cost-effective diagnosis has supported the healthcare providers to accelerate COVID screening and management. Apart from this, 5C has integrated several in-house and partner AI algorithms to create India’s largest Medical AI platform. ~50% of all scans reported on 5C are now AI-assisted.

To help the nation meet the healthcare crisis and deliver fast (Avg TAT of 24 minutes during the peak of the second wave during April and May), accurate and specialised diagnosis to lakhs of patients, 5C Network has come up with many inventive initiatives. It has created a platform called ask5c.com that enables people with mild COVID symptoms to take a second opinion by getting their reports reviewed by a network of experienced radiologists. Patients from across India have sent their scans to 5C for an expert opinion.

5C Network is one of the six startups selected for the First Cohort of the first startup collaboration program on the Edison platform, Edison[X] – Startups powered by GE Healthcare. 5C and GE Healthcare are together moving towards the mission of creating innovative solutions using contemporary technology to address the major healthcare challenges.

“GE and 5C have built a strong synergetic relationship and we have been able to expand our technology and reach with their support. We were already working with GE before and the EDISON experience only strengthened it,” states Syed S Ahmed, Co-Founder 5C Network.

Co-Founded by Syed S Ahmed and KalyanSivasailam, 5C Network has created a niche for itself in the field of diagnostic. It leveraged the strength of the digital radiology network to extend advanced quality radiology services that minimize the TATs (Turnaround times) and cost. The versatile team of the company is working day and night to improve the diagnostic ecosystem by making diagnostic reports timely, accurate and actionable. They are pioneering cutting-edge technologies to support the healthcare system to perform better. The medical technologists, competent and specialized radiologists, and an industry gold-standard structured framework of rigorous clinical audits safeguard the quality and accuracy of the reporting.. The company has saved more than 75,000 lives through emergency reporting, saved 3,000,000 waiting hours, and above 100,000 doctors have without any doubt trusted 5C’s reports.

The AI-powered diagnosticsstartup, 5C Network has created a valuable partnership with leading organizations including ASTER Group, ARM Healthcare, Sehgal Neo, Sanjeevani Hospital, Hopeberry Diagnostics, Yatharth Hospital, Bhanavi Hospital, Moolchand Hospital, and others. After receiving pre-seed and seed funding from India’s leading marquee investors Unitus Ventures, Axilor Ventures, and Ahmedabad Centre for Innovation Incubation and Entrepreneurship (CIIE), 5C Network is now aiming to secure Series-A funding from marquee investors.

The future looks bright for 5C Network. It is diligently putting its time and effort to mould the future workspace for diagnostic. This approach will solve the redundancies in the healthcare ecosystem through digital health solutions. They are also looking forward to venturing into new domains such as pathology, audiology, and cardiology markets

“NASSCOM CoEhas a very important role to play in the Indian Startup ecosystem, and 5C has been a beneficiary. It nurtures early stage companies and ideas and helped entrepreneurs build businesses around technology advantages,” comments KalyanSivasailam, Co-Founder, 5C Network.

For any further information\query you can write to us at Co-innovate@nasscom.in.

Have you ever thought of getting a view of your genetic behaviour through an astrological analogy or derive its taxonomy to get a broader perspective of your overall existence? Mapmygenome’s flagship offering “Genomepatri” studies the genetic sequence to trace the ancestral root and heritable diseases to help people revise their lifestyle choices.

Founded in 2012 by two passionate entrepreneurs Anu Acharya and Subash Lingareddy, Mapmygenome® offers advanced health solutions that are formulated by combining genetic health profiles and health history with genetic counseling. The objective of the company is to acquaint people about their health by analysing their genetic history and providing actionable steps that can assist them and the doctor’s move towards a healthier and better life.

Anu  Acharya’s entrepreneurial instincts persuaded her to start her entrepreneurial journey with Ocimum Bio solutions. This enterprising initiative was co-founded by IIT Kharagpur alumnus Subash Lingareddy. Their syndicate led to the establishment of a promising molecular diagnostics company- Mapmygenome®- one of the few companies in the country that work towards mitigating the gap between healthcare and personal health through cutting-edge technology and personal genomics. This information can help eliminate, prevent, treat and manage various types of hereditary diseases.

Backed by a powerful team of biotechnologists, statisticians, geneticists, bio informaticians, and medical counselors, Mapmygenome® brainstormed a wide spectrum of products and services, which also bestows healthcare providers with valuable information about their patients. This reduces the time and effort invested in analyzing and treating an ailment.

How do they work?

• Genomepatri Cardio: Genomics-based predictive risk assessment and management panel for cardiovascular diseases and diabetes.
• MyNutriGene: This helps in discovering the connection between genetics and diet. Through MyNutriGene individuals can conduct a detailed analysis of their eating habits which can have a huge impact on their fitness and help prevent diseases.
• MEDICAMAP: A cutting-edge pharmacogenomics test, which analyses an individual’s drug-response profile, based on genetic makeup.
• myfitgene: A program helps achieve cardio-respiratory fitness, muscle strength & endurance, body composition that aids in improving the strength and stamina of the body.
• Genomepatri Heritage: As the name suggests, this provision helps in unearthing the people’s ancestral origins. It decodes the DNA sequence and familiarizes people with their roots and their genetic behaviour.
• Genomepatri Immunity: A tool that enables users to identify gaps in immunity, including essential vitamins and minerals that contribute to immunity. This test also predicts risk for SARS-CoV and cytokine storm (adverse symptom of COVID-19).

Mapmygenome® has also invented other avant-garde offerings such as TB Test Kit, NGS Tests, Genetic Counseling, and Chromosomal Microarray Analysis (CMA). Taking a step further, the company has taken the initiative of conducting comprehensive screening of cancer using genomics. Each solution is composed of latest technology and sequencing platform that observes a simple and non-invasive sampling.

The company brought into play its creativity and innovation to mint Covisafe™- a collection kit for COVID diagnostic testing. CSIR-Centre for cellular and molecular biology validated and certified the kit to be as per ICMR protocols. The kit’s exclusive feature is the nasopharyngeal/oropharyngeal swab that is used to be placed in a stabilizing solution containing RNAShield™ (a proprietary US FDA approved reagent from US-based Zymo Research. The team designed Covisafe™ to ensure the safety of the healthcare providers and staff who collect the specimens. This kit is easy to handle and can be used in the labs. It is compatible with RNA extraction kits, does not require cold-chain transport and can be stored at temperatures less than 25 degrees for about 30 days. The kit does not allow the fluid sample to deteriorate even after passing through multiple freeze-thaw cycles.

When the first case of COVID-19 was diagnosed in India, their team worked round the clock to develop Genomepatri Immunity and an RT-PCR based COVID-19 test. They were among the first private labs in the state to offer NABL and ICMR approved tests to the public. Today, they have 2 labs (including one at Hyderabad International Airport) and many COVID-19 sample collection centers including drive-thru centers. They have expanded their portfolio to include antibody testing, rapid testing, and so forth.

Mapmygenome® has had an incredible journey of pioneering genomic technology and redefining the dimension of wellness and health by exploring individual genetic traits. The firm has created a niche for itself in the personal genomics industry, setting national and global footprints. In 2020, the company collaborated with Apollo Clinic to launch DNA-based health tests.

NASSCOM Center of Excellence IoT& AI vouchsafed Mapmygenome® with the opportunity of showcasing their successes in implementing digital technologies in healthcare, at its flagship healthcare initiative at the seventh edition of Lifesciences & Healthcare Innovation Forum (LHIF). This participation got them great interest from individuals as well as HCPs.

“Some of our recent achievements include the winning of ‘Technologies for Rural Healthcare’ category of 2019 edition, Achiever of the Pride of Telangana – 2018 awards in the Start-up category, Nasscom Emerge 50 2015 – League of 10 Profile, and many. We have bagged US$1.1 million in a pre-series A round of funding from Google India MD RajanAnandan and other angel investors in 2015 and concluded a deal that enabled us to secure around $20 million,” says Anu Acharya, Co-Founder & CEO, Mapmygenome®.

Mapmygenome® has set the bar high: it aims to expand its team, leadership, and counselling network. It endeavours to touch 100 million lives and save a million in the coming decade.

For any further information\query you can write to us at Co-innovate@nasscom.in

The pandemic has pushed us into embracing a new way of living where we remain confined and isolated. This unprecedented change has caused a severe impact on our mental and physical well-being which is why many have turned to the art of Yoga to curtail stress, enhance health, boost immunity, battle chronic diseases  and build harmony between the mind, body, and soul.

The Bangalore-based start-up, WELLNESYS is integrating ancient science with modern technology to deliver holistic wellness, assisting people to create and customize the best online and offline yoga. It puts forward a wide range of yoga learning sessions and meditation content that suits all ages, gender, and body. These sessions are curated by global experts who aspire to help people achieve the much-needed mental and physical discipline and peacefulness in times of this coronavirus pandemic.

WELLNESYS was one of the 12 start-ups which made it to the fifth edition of the Qualcomm Design in India Challenge-QDIC 2020, an initiative by Qualcomm that encourages design houses and product companies to invent useful and innovative hardware product designs incorporating Qualcomm chipset platforms and technologies. It ended the QDIC incubation as a second runner up. Qualcomm has been a very actively engaged partner of CoEIoT.

“Qualcomm Design-in-India Challenge has opened the doors for Make-in-India for our start-up. Qualcomm leadership team has been very supportive of our start-up journey, making meaningful connections, at the right time.  The patent incentive has been really helpful as we could file more patents in the process,” states MuralidharSomisetty, CEO & Founder, YogiFi.

The fountainhead of Wellnesys, MuralidharSomisetty found solace in yoga for treating his spine injury without undergoing any surgery. The miraculous advantage of this holistic science encouraged him to pursue the art and propagate it. He soon came across the underlying challenges in the adoption and effectiveness of online yoga sessions. To mitigate this problem, he masterminded an award-winning product, YogiFi to revolutionize holistic wellness in the healthcare and fitness technology landscape, making yoga an integral part of our everyday routine.

“YogiFi is here to motivate, guide, and help every individual adopt the culture and exercise the healing power of yoga; guiding them towards a healthy and happy lifestyle. During the pandemic, the YogiFi app delivered at-home interactive yoga sessions using computer vision (camera of a smartphone) besides the smart mat solution with patented asana tracking technology. Each session is curated based on the insightful data and various metrics gathered from the mat: strength, alignment, flexibility, and endurance. Users can now understand the effectiveness of the yoga session with vitals data correlated from wearables such as Apple Watch,” he adds.

The start-up has leveraged technologies like Sensors, IoT, edge computing, AI, Computer Vision, and Apps to create an absolute wellness solution that synthesizes a nonpareil online and offline yoga studio experience at home. Its smart and eco-friendly yoga mats are sensor-equipped and are designed to be paired with the mobile app for enabling an interactive and immersive yoga class experience. These yoga mats can be connected with YogiFi App that acts like personal trainers, extending advanced interactive sessions, tracking the user’s activity & progress, and give real-time feedback on postures and flexibility. YogiFi delivers interactive and immersive yoga classes straight to an individual’s home using the fusion of smart mat and computer vision. YogiFi’s Virtual Studio feature in the app transports users (virtually) to exotic landscapes such as the Himalayas, Forest, Beach, and more by using AR/VR technology. This innovative solution is called “Yoga By Nature” and creates a real-life learning experience amidst a virtual yet aesthetic ambiance. YogiFi is also looking at launching a feature soon to enable user to practice along with a personal trainer or even participate in a fun challenge with any of their friends or peers on the YogiFi’s community leader board. It is compatible with wearables such as Apple Watch, FitBit for biofeedback and well-integrated with smart ecosystem products such as Google Home, Smart TV and others.

Within two years of its establishment, YogiFi has set a strong foot in the international market and has been successful in its endeavour of becoming a smart wellness companion, delivering technology-enabled solutions that are accessible by everyone, anywhere, and at any time. This initiative has won the company an array of innovation awards and global recognition with multiple media mentions.

Under the aegis of the Make-in-India initiative and local assembly line, YogiFi envisages developing a lighter version of the product that is affordable and fits into the price-sensitive markets such as India, Asia-Pacific region.  It aims to make yoga classes accessible across socio-geo-demographic boundaries and gamify the learning process through modern technologies.

For any further information\query you can write to us at Co-innovate@nasscom.in

The word cancer has been tormenting families for many centuries now. The diagnosis of this disease causes a lot of physical and psychological distress to patients and their families. Founder & CEO of CARER, Samara Mahindra’s subjective encounter with cancer has been an eye-opener where she realized that there were only methodical approaches availed for treating cancer and no emphasis is given to the quality of life or measures that can effectively support pre-cancer and post-cancer treatment. Intending to provide the sick and their family the support they need in their cancer journey, Samara along with a masterly team of Oncologists, Patients, and Science structured the foundation of Personalized Cancer Care providing platform- CARER that aims to be a ray of hope for people battling cancer and helping them heal, feel and live better.

Headquartered in Bangalore, CARER is on its mission of establishing a unique AI-driven integrative oncology health tech solution that will focus on 360-degree interactivity and connection between every health service provider, partner & patient, in-depth health tracking, therapeutic intervention, community building, data and content management. It offers an extensive range of programs that can be categorized into three parts-Integrative therapy for treatment, Integrative therapy for post-treatment, and Nutrition for Cancer.

The efficient team of Carer put their brains together to think up exclusive methodologies and therapies that consist of Nutrition Therapy, Movement & Meditation Therapy, and Mental Well-Being Therapy. One can also find recipe books, Cancer Essentials Guidebook, and other quality products that suit the needs of the patients at the CARER store. Since day one, CARER has been diligently working towards building credibility and evidence through clinical trials and patient pilot studies. They have curated a unique methodology that has proven to enhance cancer patients’ condition in multiple factors and parameters, curtailing their side-effects, improving immunity, and ensuring better treatment outcomes.

Additionally, CARER is advancing services to support patients recovering and healing from COVID as well as cancer. “At CARER, we made sure to provide services that supported efficient delivery of services and immediate response to our patients through technology. We have created certain specific therapeutic interventions for COVID-positive cancer patients and have partnered with other homecare service providers to make sure that our patients are getting access to high quality COVID care at home,” Samara Mahindra, Founder & CEO of CARER.

CARER started its journey in the year 2018 and in two years it has carved a niche for itself in the industry. The startup has to date treated over 400 cancer patients with 43 different cancer types.  It has partnered with doctors, home care providers, diagnostic chains, genetic testing labs, pharmaceutical companies, and more than 10 leading hospital chains across the country suchas Fortis, Manipal, Aster CMI, NH, and others. This technology-driven platform has established a firm global presence and worked with patients in different parts of the world, from UK, US, Africa, South East Asia to the Middle East. Among the many projects, CARER had executed a prominent clinical pilot with HCG Hospital for patients suffering from head and neck cancer. The results of this study are being admitted for publication. Furthermore, CARER has secured seed funding in its very founding year.

“Our partnership with a reputable technology company and their connectivity with the international healthcare market has proven to be beneficial for us. This association helped us to have a better grasp of the healthcare ecosystem and following suit with the scientific methodologies that are enabled by technologies and are being developed all around the world. They have guided CARER to create a transformational integrative oncology solution, for the first time here in India. We are the first and only company that provides integrative oncology solutions to cancer patients,” she adds.

CARER has visualized its strategy towards building the largest integrative oncology technology platform that is AI and data-driven and completely focused on retrieving deeper clinical and non-clinical data points. The company will also be dedicating a section of its man oeuvres to recognizing larger clinical trials and R&D, along with brand building and patient acquisition.

“NASSCOM has been a great support system in encouraging and assisting companies such as ours that are trying to make a massive impact and solution-driven to change the way healthcare is administered. We are often connected to other large healthcare entities for various projects, through NASSCOM, which might not have been possible or as easy otherwise. The team has been extremely supportive and has taken a personal interest in helping us build valuable propositions for various projects.” Samara Mahindra, Founder & CEO of CARER.

For any further information\query you can write to us at Co-innovate@nasscom.in

Systematic integration of technology has utterly revamped the way medical care is conferred to patients, enhancing patient-physician interaction, and making healthcare more accessible & flexible than before. At the current set of circumstances where the entire world is grappling with a healthcare crisis, technology like Artificial Intelligence has helped in reducing the time spent in executing healthcare management activities at the fraction of the price.

Healthtech startup AarogyaAI is using AI-enabled software for expediting diagnosis and enabling personalized treatment within a few hours. Founded by two promising innovative women entrepreneurs Dr. Praapti Jayaswal and Avlokita Tiwari, AarogyaAI will combat lethal infectious diseases like Tuberculosis and develop an AI-driven software to diagnose Drug-resistant Tuberculosis, expediting the process of diagnosis and effective treatment.

AarogyaAI is one of the six startups that have graduated from the India Edison™ Accelerator, Cohort 2- GE Healthcare’s second startup-collaboration program that intends to nurture the startup ecosystem and work with them to create innovative and effective healthcare solutions.

The AarogyaAI software innovated by the company is deployed in the GE Edison platform. It is empowered with a Machine Learning algorithm that has the ability to make sense of complex genomic data and output an easy to comprehend drug sensitivity report which augments clinical decision-making. Thus, each patient’s antibiotic prescriptions are customized to their specific need.

“Artificial intelligence helps convert large amounts of complex data to concise factoids that can augment a doctor’s clinical decision making. The AarogyaAI’s SaaS requires minimal infrastructure and basic training to operate and can report a copper-bottomed patient’s drug susceptibility status in a few hours,” states Dr. Praapti Jayaswal, Co-Founder & CEO, AarogyaAI.

Since inception, AarogyaAI has created a buzz in the ecosystem. The firm has secured investment from one of the largest genomics companies in the world, Illumina Inc., USA. In 2019, the team at AarogyaAI was awarded the Best Pitch by Shakti – The Empathy Project. It made its way to be a part of the San Francisco-based Illumina Accelerator Program in 2020. In March 2020, AarogyaAI also won the BIRAC TiE WInER Award which is accredited to Women in Entrepreneurial Research by the Biotechnology Industry Research Assistance Council (BIRAC).

In addition, winning awards like the Indo-Sweden Healthcare Innovation Challenge, organized by the Ministry of Health and Family Welfare, Government of India, and getting on board in the GE Healthcare’s Indian Edison^TM Accelerator platform has gained it national as well as international level recognition.

“We established AarogyaAI in 2019, with the sole purpose of revolutionizing the method of treating Tuberculosis and saving lives. We have partnered with leading diagnostic labs & hospitals in India for building & validating the product. Eventually, we aim to anticipate the evolution, nature, and pattern of the bacteria, along with predicting the future drug resistance structure. We leverage AI/ML and genomics, to rapidly and comprehensively diagnose drug resistance in infectious diseases. We also intend to use AI, ML, and IoT technologies to ensure that patients even in the most remote corner of India, have access to the latest diagnostics and treatment options,” states Avlokita Tiwari, Co-Founder, AarogyaAI.

With a vision to contribute to ending tuberculosis globally, the founders are driven by the concept of translation of research into real-world application. AarogyaAI envisions assimilating years of research to combat antimicrobial resistance in infectious diseases. The company wants to employ cutting-edge technology – genomics and AI to ensure patients are provided precision diagnosis to enable effective medication. The intention is to collaborate with centers from different geographical locations in India, and abroad; and expand the database on more first and second-line anti-TB drugs. The AarogyaAI solution will be able to predict new mutations that confer drug resistance in the bacteria. AarogyaAI aims to impact human health and build facilities where no one is subjected to incorrect medication and is left to deal with very harmful side effects.

“AarogyaAI is on a vision to develop a time and cost-effective test for the drug-resistant tuberculosis. Their technology will go a long way in addressing the appropriate management of the disease burden and potentially contributing to the ending of the TB epidemic by 2030, which is one of the heath targets of the United Nations Sustainable Development Goals.” Abhijit Patil, Senior Director – AI & Analytics: Advanced Technology Group @ GE Healthcare and India EdisonTM Accelerator Cohort 2 Mentor.